Pharmacokinetics of once-daily dolute-gravir and ritonavir-boosted darunavir in HIV patients: the DUALIS study

被引：10
|
作者：
Spinner, Christoph D. [1 ,2 ]
Kuemmerle, Tim [3 ]
Krznaric, Ivanka [4 ]
Degen, Olaf [5 ]
Schwerdtfeger, Christiane [1 ,2 ]
Zink, Alexander [2 ,6 ]
Wolf, Eva [7 ]
Klinker, Hartwig H. F. [8 ]
Boesecke, Christoph [2 ,9 ]
机构：
[1] Univ Hosp Klinikum Rechts Isar, Dept Med 2, Ismaninger Str 22, D-81675 Munich, Germany
[2] German Ctr Infect Res DZIF, Braunschweig, Germany
[3] Univ Hosp Cologne, Dept Med 1, Kerpenerstr 62, D-50937 Cologne, Germany
[4] Zentrum Infektiol Prenzlauer Berg ZIBP, Driesenerstr 20, D-10439 Berlin, Germany
[5] Univ Klinikum Hamburg Eppendorf, Infect Dis Unit, Martinistr 52, D-20246 Hamburg, Germany
[6] Univ Hosp Klinikum Rechts Isar, Dept Dermatol & Allergol, Ismaninger Str 22, D-81675 Munich, Germany
[7] MUC Res, Karlspl 8, D-80335 Munich, Germany
[8] Univ Wurzburg, Med Ctr, Div Infect Dis, Dept Med 2, Oberduerracherstr 6, D-97080 Wurzburg, Germany
[9] Bonn Univ Hosp, Dept Med 1, Sigmund Freud Str 25, D-53127 Bonn, Germany
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2017年 / 72卷 / 09期
关键词：
SIMULTANEOUS QUANTIFICATION; INHIBITOR; PLASMA;
D O I：
10.1093/jac/dkx105
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：2679 / 2681
页数：4
相关论文
共 50 条
  • [41] Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity
    Casado, Jose L.
    Banon, Sara
    Rodriguez, Miguel A.
    Santiuste, Carmen
    Perez-Elias, Maria J.
    Moreno, Ana
    Moreno, Santiago
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (02) : 630 - 632
  • [42] Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO
    Molina, Jean-Michel
    Clotet, Bonaventura
    van Lunzen, Jan
    Lazzarin, Adriano
    Cavassini, Matthias
    Henry, Keith
    Kulagin, Valeriv
    Givens, Naomi
    Brennan, Clare
    de Oliveira, Carlos Fernando
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2014, 17 : 6 - 7
  • [43] Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study
    Winston, Alan
    Faetkenheuer, Gerd
    Arribas, Jose
    Hill, Andrew
    van Delft, Yvon
    Moecklinghoff, Christiane
    [J]. HIV CLINICAL TRIALS, 2010, 11 (03): : 163 - 169
  • [44] Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
    Dailly, Eric
    Tribut, Olivier
    Tattevin, Pierre
    Arvieux, Cedric
    Perre, Philippe
    Raffi, Francois
    Jolliet, Pascale
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (07) : 523 - 526
  • [45] Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
    Punyawudho, Baralee
    Thammajaruk, Narukjaporn
    Ruxrungtham, Kiat
    Avihingsanon, Anchalee
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 49 (03) : 327 - 332
  • [46] Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients
    Eric Dailly
    Olivier Tribut
    Pierre Tattevin
    Cédric Arvieux
    Philippe Perré
    François Raffi
    Pascale Jolliet
    [J]. European Journal of Clinical Pharmacology, 2006, 62 : 523 - 526
  • [47] Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
    Mills, Anthony M.
    Nelson, Mark
    Jayaweera, Dushyantha
    Ruxrungtham, Kiat
    Cassetti, Isabel
    Girard, Pierre-Marie
    Workman, Cassy
    Dierynck, Inge
    Sekar, Vanitha
    Abeele, Carline Vanden
    Lavreys, Ludo
    [J]. AIDS, 2009, 23 (13) : 1679 - 1688
  • [48] Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment
    Stellbrink, Hans-Juergen
    Le Fevre, Eric
    Carr, Andrew
    Saag, Michael S.
    Mukwaya, Geoffrey
    Nozza, Silvia
    Valluri, Srinivas Rao
    Vourvahis, Manoli
    Rinehart, Alex R.
    McFadyen, Lynn
    Fichtenbaum, Carl
    Clark, Andrew
    Craig, Charles
    Fang, Annie F.
    Heera, Jayvant
    [J]. AIDS, 2016, 30 (08) : 1229 - 1238
  • [49] DRUG RESISTANCE PROFILES OF HIV-1 POSITIVE PATIENTS EXPERIENCING VIROLOGICAL REBOUND ON RITONAVIR-BOOSTED DARUNAVIR MONOTHERAPY
    Abdullahi, A.
    Fopoussi, O. M.
    Beloukas, A.
    Defo, V. F.
    Moudourou, S.
    Kouanfack, C.
    Torimiro, J.
    Geretti, A. M.
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2019, 113 : S211 - S212
  • [50] Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial
    Venter, Willem D. F.
    Moorhouse, Michelle
    Sokhela, Simiso
    Serenata, Celicia
    Akpomiemie, Godspower
    Qavi, Ambar
    Mashabane, Nonkululeko
    Arulappan, Natasha
    Sim, Joel W.
    Sinxadi, Phumla Z.
    Wiesner, Lubbe
    Maharaj, Ellisha
    Wallis, Carole
    Boyles, Tons
    Ripin, David
    Stacey, Sarah
    Chitauri, Gila
    Hill, Andrew
    [J]. LANCET HIV, 2019, 6 (07): : E428 - E437
12345